Mina Bahram et al. reported that administration of 6 mg melatonin had a refinement impact on non-alcoholic fatty liver disease (NAFLD) features such as imbalance anthropometric measurements, high blood pressure, abnormal liver enzymes, high sensitive C-reactive protein (hs-CRP), and abnormal leptin levels [194]. The gene discussed is LEP; the disease is metabolic dysfunction-associated steatotic liver disease.